Venetoclax plus rituximab increases progression-free survival in relapsed chronic lymphocytic leukemia
1. Patients with relapsed or remitting chronic lymphocytic leukemia (CLL) treated with venetoclax-rituximab had a greater 2-year progression-free survival rate compared ...